1. Home
  2. STKE vs MAIA Comparison

STKE vs MAIA Comparison

Compare STKE & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sol Strategies Inc.

STKE

Sol Strategies Inc.

SELL

Current Price

$1.31

Market Cap

67.9M

Sector

N/A

ML Signal

SELL

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

SELL

Current Price

$1.10

Market Cap

69.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
STKE
MAIA
Founded
2002
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.9M
69.2M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
STKE
MAIA
Price
$1.31
$1.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $12.00
AVG Volume (30 Days)
442.0K
★ 565.0K
Earning Date
01-28-2027
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.33
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.85
$0.87
52 Week High
$3.95
$3.19

Technical Indicators

Market Signals
Indicator
STKE
MAIA
Relative Strength Index (RSI) 42.92 33.53
Support Level $1.00 N/A
Resistance Level $1.37 $1.47
Average True Range (ATR) 0.14 0.05
MACD -0.05 -0.01
Stochastic Oscillator 9.02 9.37

Price Performance

Historical Comparison
STKE
MAIA

About STKE Sol Strategies Inc.

Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: